We asked our Foolish writers for their top ideas for May. Their picks include Magna International (TSX:MG)(NYSE:MGA) and Algonquin Power & Utilities (TSX:AQN)(NYSE:AQN). Click here to see the rest!
Image source: Getty Images.
Village Farms International(TSX:VFF)(NASDAQ:VFF) is one of the largest and longest-operating vertically integrated greenhouse growers in North America and the only publicly traded greenhouse produce company in Canada. The company owns one of the single largest cannabis growing operations in the world, one of the lowest-cost greenhouse producers, and one of the best-selling brands in Canada.
Growth by acquisition
Pure Sunfarms, which was acquired by Village Farms, leverages the company’s 30 years of experience as a vertically integrated greenhouse grower for the rapidly developing cannabis opportunity in Canada. Pure Sunfarms is currently one of the largest producers of cannabis in Canada with distributions in five provinces. The company’s long-term objective is to be the leading low-cost, high-quality cannabis producer in Canada.
OrganiGram Holdings Inc. (NASDAQ: OGI)Village Farms International, Inc.
Village Farms International, Inc. is a greenhouse grower that is leveraging its low-cost agriculture techniques into opportunities in the cannabis and CBD markets In North America. Specifically, Pure Sunfarms the companyâs wholly-owned subsidiary is one of the largest cannabis operations in North America. Pure Sunfarms is one of the best-selling brands of cannabis and has managed to generate 9 quarters of positive adjusted EBITDA since commencing sales. In its most recent financials, Pure Sun Farms saw 28% sequential growth in Q4 branded cannabis sales. Additionally, Pure Sun Farms saw 248% growth year over year with retail branded sales of $15.5 million. In total Village, Farm reported fourth-quarter revenue of $47.4 million a 43% increase from the prior year. But this fell short of the consensus estimate analysts gave of $53.1 million.
The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
ALANA PATERSON/The New York Times News Service
Shifting brand loyalty and increasing popularity for better-quality cannabis products are hampering the growth prospects of some of the largest cannabis companies in Canada – despite an overall boost in sales of legal recreational cannabis throughout the pandemic.
Last week, both Aphria Inc. and Organigram Holdings Inc. reported weaker-than-expected quarterly revenues driven by lower domestic demand for their products.
How Growing Number Of Clinical Trials Are Influencing Growth Of The Cannabis Pharmaceuticals
News provided by
Share this article
Financialnewsmedia.com News Commentary
PALM BEACH, Fla., April 14, 2021 /PRNewswire/ The medical cannabis market has made some remarkable accomplishments in the past few years with the launch of innovative products. The clinical trials and approval of some cannabis-infused products have opened up the market for cannabinoid-based pharmaceuticals. The market for cannabis pharmaceutical is still in the nascent phase with higher opportunities. The growing legalization of marijuana globally is encouraging more investment in the space, and for pharmaceutical companies to expend more resources on the development of cannabinoid-based pharmaceutical drugs. A report from Grand View Research projected that the global cannabis pharmaceuticals market size was valued at USD 67.0 million in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 76.